Drug intelligence / Profile preview

ANS05

Development stage: Preclinical
Lead developer: Avistone Biotechnology
Modality: Small Molecules

Overview

ANS05 is a preclinical-stage small molecule inhibitor of the Human Epidermal Growth Factor Receptor 2 (HER2), developed by Avistone Pharmaceutical (Ningbo) Co., Ltd. The compound is specifically engineered to target HER2 mutations and amplifications, which are prevalent drivers in various solid tumors. Its primary development focus includes non-small cell lung cancer (NSCLC) with HER2 mutations, as well as breast and gastric cancers characterized by HER2 amplification. As a precision oncology candidate, ANS05 aims to inhibit the kinase activity of HER2 to suppress tumor growth and progression in patients with these specific genetic profiles.

Targets

HER2 exon 20 ins (Human epidermal growth factor receptor 2 (HER2) exon 20 insertion mutants)

Beyond the preview

Go deeper on ANS05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANS05.

Explore the full profile